

ASX Announcement

Share Consolidation and the Company's ASX Code

Wellnex Life Limited (**ASX: WNX**) advises that on 26 September 2024, shareholders of the Company approved the consolidation of the Company's issued capital on a fifty for one (50:1) basis. The last day for trading on a pre-consolidation basis was 8 October 2024.

In accordance with the timetable announced to the ASX on 28 August 2024, trading in the Company's securities take place from today on a post-consolidation and deferred settlement basis.

The Company's ASX code will be 'WNXDA' on the ASX platform whilst trading is on a deferred settlement basis.

Normal trading commences on Monday, 18 October 2024 under ASX code 'WNX'.

For more information, please refer to the Company's Notice of Extraordinary General Meeting released to the ASX on 28 August 2024.

This announcement was approved by the Board of Directors

-ENDS-

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX) George Karafotias

Chief Executive Officer P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and

globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/